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ABSTRACT 
 
 
Bricker, Rebecca Lynn. M.S., Microbiology and Immunology Program, Wright State 
University, 2012.  Q-VE-OPh, a control caspase inhibitor for analyzing neuronal death. 
 
Sarin is a neurotoxin that has been used in terrorist attacks in Japan and is a 
potential bioterrorist weapon.  It induces seizures by affecting the regulation of 
neurotransmitters in the brain.  Seizures are directly correlated to neuronal damage. Two 
types of neuronal damage that can occur are apoptosis and necrosis.  One of the main 
regions of the brain where neuronal death occurs is the hippocampus, which is involved 
in memory.  Victims showed chronic decline of memory loss 3 and 7 years after the 
Tokyo’s terrorist attack incident.  There are treatments available that can break down 
sarin or can block the continuous activation of acetylcholine by acting as a competitive 
antagonist at the acetylcholine receptor, but there are no current treatments that prevent 
neuronal death in the brain after sarin exposure. Our overall hypothesis is that the broad 
spectrum caspase inhibitor, Quinoline-Val-Asp-Difluorophenoxymethyl ketone (Q-VD-
OPh), can reduce or prevent caspase-activated neuronal death in the brain thereby, 
preventing memory loss.  Q-VD-OPh has been shown to prevent all apoptotic pathways 
and is not toxic to cells.  It is the most effective known caspase inhibitor and has the 
ability to cross the blood brain barrier.  In order to validate its effectiveness in preventing 
neuronal death in sarin-exposed mice, we designed and synthesized the appropriate 
iv 
 
negative control by replacing aspartic acid in Q-VD-OPh with glutamic acid, making Q-
VE-OPh.  Q-VE-OPh did not prevent DNA laddering or the activation of cleaved caspase 
8 or 9.  In addition, we found Q-VE-OPh is not toxic in vitro.  Q-VE-OPh closely 
resembles Q-VD-OPh which provides it as an optimal negative control.  Sarin-exposed 
mice brains treated with Q-VD-OPh or Q-VE-OPh will be analyzed by 
immunohistochemistry. 
Due to the use of sarin being restricted to two locations in the United States by the 
US Department of Defense, all of our experiments must be done at one time and at the 
same facility.  Therefore, it was necessary to optimize brain tissue processing techniques, 
storage conditions, and the immunohistochemistry assays in mice not exposed to sarin.  
The goal of the current work will focus on eliminating background in 
immunohistochemistry assays in order to prevent false labeling.  The optimizations of 
these labeling procedures will be used to determine if neuronal death in the hippocampus 
is decreased in sarin-exposed mice treated with Q-VD-OPh compared to sarin-exposed 
mice treated with Q-VE-OPh. 
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I. INTRODUCTION 
What is Sarin? 
Sarin, also known as GB, is an organophosphorous cholinesterase inhibitor that is 
used as a human-made chemical warfare nerve agent (Figure 1).  It is part of the G-series 
compounds named after German scientists.  It is an odorless and colorless gas that people 
can be exposed to through inhalation of vapors or contact with the liquid form.  Due to 
being the most volatile of the nerve agents, sarin is the preferred chemical warfare agent.  
It has a vapor pressure of 2.1 mm Hg which is 16 times higher than other nerve agents 
and can remain active in the environment for 2 to 24 hours.  Sarin can also produce a 
rapid response, with symptoms occurring from seconds to minutes after exposure 
(Wiener and Hoffman, 2004). 
 
History 
The first organophosphate compounds were synthesized in 1854 and the first 
nerve agents were developed in 1936.  Nerve agents were originally developed as 
pesticides.  By the end of World War II, German scientists had developed more types of 
nerve agents and produced large quantities that could be deployed as weapons.  The 
United States and Soviet Union developed their own stockpiles of nerve agents in the 
1950’s.  In 1984, Iraq had used nerve agents in their war against Iran (Wiener and 
Hoffman, 2004).  The biggest incidents in which nerve agents were used were in two  
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Figure 1: Chemical structure of sarin 
Sarin is an organophosphate cholinesterase inhibitor. 
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Figure 1 
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terrorist attacks in Japan (Wiener and Hoffman, 2004).  In 1994, the religious cult Aum 
Shinrikyo released twelve liters of 70% sarin in a residential area in the city of 
Matsumoto, Japan (Nakajima et al., 1998).  More than 250 people were exposed of which 
56 were admitted to hospitals and 7 people died (Suzuki et al., 1997).  A second, much 
larger attack occurred in 1995 when the same religious cult released 30% sarin in five 
subway cars on three separate subway lines during the Monday morning rush hour 
underneath the Japanese National Government’s ministry offices in Tokyo, Japan.  In this 
attack, 5,500 people needed medical care and 12 died (Yanagisawa et al., 2006). (Table 
1) 
 
Effects of Sarin on People 
The people exposed to sarin in the terrorist attacks died due to respiratory failure 
and severe anoxic brain damage (Yanagisawa et al., 2006).  Mild symptoms included 
nausea, vomiting, headache, sore throat, constricted pupils, ocular pain, numbness in the 
extremities, and respiratory difficulty.  The more severely exposed patients experienced 
the mild symptoms as well as scattered fasciculation, hallucination, generalized 
convulsions, transient cardiac arrhythmias, and a decreased level of consciousness 
(Figure 2).  The major laboratory finding was a decrease in plasma cholinesterase 
activity.  Recovery of plasma cholinesterase to normal levels took between 2-3 months 
(Okumura et al., 1996; Murata et al., 1997; Suzuki et al., 1997; Nakajima et al., 1998; 
Morita et al., 2005; Yanagisawa et al., 2006).  Victims from Matsumoto were relieved of 
major symptoms and released from the hospital after a month.  Mild symptoms still 
occurred up to 6 months to a year in a few sarin-exposed people in  
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Table 1: History of sarin 
Date Event 
1854 Originally developed in Germany as a pesticide. 
1936 First nerve agents were developed. 
1945 Germany produced large quantities that could be deployed as weapons. 
1950 US and Soviet Union obtained their own stockpiles of nerve agents. 
1984 Iraq used nerve agents in their war against Iran. 
1991 Labeled as a “Weapon of Mass Destruction” by the United Nations. 
1994 The religious cult Aum Shinrikyo released twelve liters of 70% sarin in a 
residential area in the city of Matsumoto, Japan. 
1995 The religious cult Aum Shinrikyo released 30% sarin in subway cars 
underneath the Japanese National Government’s ministry offices in Tokyo, 
Japan. 
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Figure 2: Summary of symptoms from sarin exposure 
Sarin affects the central and peripheral nervous system.  Mild symptoms included 
nausea, headache, sore throat, constricted pupils, ocular pain, numbness in the 
extremities, and respiratory difficulty.  The more severely exposed patients experienced 
the mild symptoms plus scattered fasciculation, hallucination, generalized convulsions, 
transient cardiac arrhythmias, and a decreased level of consciousness. 
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Figure 2 
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Matsumoto (Nakajima et al., 1998; Morita et al., 2005).  People who had a pupil diameter 
of less than 2mm and a serum cholinesterase level less than 100% were evaluated a year 
later.  Most had normal results but the more severe patients had electroencephalogram 
(EEG) abnormalities that took up to 5 years to return to normal (Yanagisawa et al., 2006).  
In the Tokyo attack, 95% of people admitted were released from the hospital within 2-4 
days (Okumura et al., 1996).  Five years after sarin poisoning, many still had common 
symptoms such as blurred vision, easy fatigability, difficulty in concentration, difficulty 
in near vision, and headaches (Murata et al., 1997; Yanagisawa et al., 2006).  
Importantly, people exposed to sarin that were evaluated 3 and 7 years afterwards, 
showed chronic decline of memory function compared to people who were not exposed 
to sarin. (Nishiwaki et al., 2001; Miyaki et al., 2005). 
 
Mechanism 
  A single nerve impulse in the terminal motor-axon releases acetylcholine which 
binds to its receptors and produces a localized depolarization that stimulates a muscle 
response.  This response is terminated when acetylcholinesterase degrades acetylcholine, 
releasing acetylcholine from its receptor (Figure 3a).  Sarin binds to and inhibits the 
enzyme acetylcholinesterase, preventing acetylcholine from being degraded (Figure 3b).  
As a result, acetylcholine builds up and constantly activates its receptor.  This causes 
continuous transmission of nerve impulses that prevent the muscle or organ from 
relaxation, which contributes to seizures (Taylor 1985; Khan 2000; O’Donnell et al., 
2010).  Ten hours after sarin exposure, sarin can release a functional group making the 
bond between sarin and acetylcholinesterase permanent.  The enzyme,  
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Figure 3: Acetylcholine mechanism to trigger nerve impulses 
A single nerve impulse in the terminal motor-axon releases acetylcholine which 
binds to its receptors and produces a localized depolarization that stimulates a muscle 
response.  This response is terminated when acetylcholinesterase degrades acetylcholine 
releasing it from its receptor (A).  Sarin binds to and inhibits the enzyme 
acetylcholinesterase which prevents acetylcholine from being degraded (B). 
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Figure 3 
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acetylcholinesterase, is said to be ‘aged’ and cannot be reactivated.  The function of the 
enzyme returns once new, unbound acetylcholinesterase has been produced (Wiener and 
Hoffman, 2004). 
 
Treatment 
There are a few drugs that are used for treatment of sarin nerve poisoning.  
Atropine blocks further acetylcholine activation through competitive antagonism with 
acetylcholine at its receptor (Figure 4a).  Pralidoxime restores acetylcholinesterase by 
breaking down the nerve agent bound to it (Figure 4b).  The use of pralidoxime is only 
effective before the enzyme has aged.  Diazepam (Valium) is an anticonvulsant drug that 
reduces convulsions and seizures.  People who are at a potential risk for chemical 
exposure, such as the military, are provided with a Mark I nerve agent antidote kit 
(NAAK) (Figure 5a).  This consists of 2 auto-injectors that contain atropine and 
pralidoxime.  There is also an additional auto-injector called convulsion antidote, nerve 
agent (CANA) that contains diazepam (Figure5b).  These auto-injectors are injected into 
the muscle of the thigh or buttock by the individual after exposure (Wiener and Hoffman, 
2004).   
 
Seizures cause brain damage 
In rats exposed to sarin, 70% that had prolonged convulsions lasting longer than 2 
hours also developed brain lesions or neuronal death.  Brains lesions were less severe in 
rats that only had partial seizures.  Lesions were found mainly in CA1 and CA3 regions 
of the hippocampus 4 hours post exposure and subsequently in the thalamus and piriform  
12 
 
Figure 4: Treatment for sarin poisoning. 
Atropine blocks further acetylcholine activation through competitive antagonism 
with acetylcholine at its receptor (A).  Pralidoxime restores acetylcholinesterase by 
breaking down the nerve agent bound to it (B). 
 
Atropine = A 
Pralidoxime = P 
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Figure 4 
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Figure 5: Mark I nerve agent antidote kit (NAAK) and convulsion antidote, nerve 
agent (CANA) 
People who are at a potential risk for chemical exposure, such as the military, are 
provided with a Mark I nerve agent antidote kit (NAAK) (A).  This consists of 2 auto-
injectors that contain atropine and pralidoxime.  There is also an additional auto-injector 
called convulsion antidote, nerve agent (CANA) that contains diazepam (B). 
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Figure 5 
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cortex 24 hours post exposure.  The hippocampus is involved in spatial learning and 
memory (Kadar et al., 1995).  Sarin-exposed rats had impaired working and reference 
memory 1 month post exposure and no recovery of function was detected 6 months post 
exposure in water maze memory task (Grauer et al., 2008).  Seizures are due to an 
increase in excitatory activity which can cause brain damage (Lallement et al., 1992; 
Allon et al., 2011).  Although atropine and pralidoxime prevent further acetylcholine 
activation and diazepam enhances inhibitory activity to suppress seizures, there are no 
current drugs that inhibit neuronal death in the brain after sarin exposure. 
 
Neuronal Death 
There are different types of neuronal death found in brain lesions after sarin 
exposure that could occur: apoptosis and necrosis (Bonfoco et al, 1995; Charriaut-
Marlangue et al., 1996; Leist et al, 1997; Chen et al., 1998; Fujikawa et al.,1999; 
Colbourne et al., 2000; Fujikawa et al., 2000; Henshall et al., 2000; Kondratyev et al., 
2000; Benchoua et al, 2001; Niquet et al., 2007; Fujikawa et al., 2010; Lopez-Meraz et 
al., 2010a; Lopez-Meraz et al., 2010b).  These types of cell death are a form of 
programmed cell death that is essential for development, morphogenesis, tissue 
remodeling, immune regulation, and occurs in many types of pathologies (Fiers et al., 
1999).  Excessive death can contribute to injury which is found to occur in several 
diseases such as sepsis, stroke, ischemia, neurodegenerative diseases, diabetes, and 
myocardial infarction (Mattson 2000; Duprez et al., 2009).   
Apoptosis is the controlled breakdown of the cell into apoptotic cell bodies which 
are then rapidly recognized and engulfed by surrounding cells and phagocytes.  This 
17 
 
process is characterized by cell shrinkage, membrane blebbing, nuclear and cytosolic 
condensation, the breakdown of nuclear DNA, and the lack of an inflammatory response 
(Fiers et al., 1999; Duprez et al., 2009).  There are two apoptotic pathways: intrinsic and 
extrinsic.  The intrinsic (mitochondrial) pathway is activated by DNA damage and 
cytotoxic insult that act through the mitochondria.  When there is cellular stress, 
cytochrome c is released from the mitochondria and associates with apoptotic protease 
activating factor - 1 (Apaf-1), adenosine triphosphate (ATP), and initiator procaspase 9 to 
form the apoptosome.  The apoptosome activates caspase 9 which leads to the cleavage 
and activation of executioner caspases 3, 6, and 7.  The extrinsic (death receptor) 
pathway is activated by the stimulation of death receptors which activate the death-
inducing signaling complex (DISC).  DISC has a Fas-associated death domain (FADD) 
that recruits and activates initiator caspases 8 and/or 10 which then activate the 
executioner caspases 3, 6, and 7.  Cysteine-aspartic proteases or caspases mediate 
apoptosis (Figure 6) (Kajta 2004; Ribe et al, 2008; Duprez et al., 2009).  
Necrosis is caspase independent and is characterized by cytoplasmic and 
organelle swelling, loss of cell membrane integrity, nuclear pyknosis, small dispersed 
clumps, and the release of cellular contents into extracellular space (Fiers et al., 1999; 
Henshall et al., 2000; Duprez et al., 2009).  It occurs when cells are exposed to extreme 
stress or in neurodegenerative disorders (Syntichaki et al, 2003).  Necrotic cell death can 
be activated if caspase activation during apoptosis is hampered and can then serve as a 
backup pathway via the death receptors (Duprez et al., 2009). 
There is controversy over which type of cell death occurs after seizure (Henshall 
2007; Wyllie and Golstein 2001; Sperandio et al., 2000; Martin et al., 1998; Leist and  
18 
 
Figure 6: Apoptotic Pathway 
There are two apoptotic pathways: intrinsic and extrinsic.  The intrinsic 
(mitochondrial) pathway is activated by DNA damage and cytotoxic insult that act 
through the mitochondria.  When there is cellular stress, cytochrome c is released from 
the mitochondria and associates with apoptotic protease activating factor - 1 (Apaf-1), 
adenosine triphosphate (ATP), and initiator procaspase 9 to form the apoptosome.  The 
apoptosome activates caspase 9 which leads to the cleavage and activation of executioner 
caspases 3, 6, and 7.  
The extrinsic pathway (B) is activated by the stimulation of death receptors which 
activate the DISC.  DISC recruits and activates initiator caspases 8 and/or 10 which then 
activate the executioner caspases 3, 6, and 7.  Caspases 3, 6, and 7 execute the last phase 
of apoptosis. 
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Figure 6 
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Jäättelä 2001; Nicotera et al., 1999; Fujikawa 2000a; Lee et al., 2000; Choi 1996; Choi 
1995; Seo et al., 2009).  There are several factors that influence the type of cell death that 
occurs: maturity, intensity, and energy levels.  The CA1 region matures, physiologically 
and anatomically, quicker than the dentate gyrus.  In postnatal hippocampal neurons in 
rats that were induced to have seizures, the CA1 region died necrotically whereas the 
dentate gyrus died apoptotically (Lopez-Meraz et al., 2010b).  Low levels of excitotoxic 
exposure can induce neurons to undergo apoptosis whereas more intense excitotoxic 
exposures deplete the energy supply and induced necrosis (Bonfoco et al, 1995).  This is 
because ATP acts as a switch between apoptosis and necrosis.  In cell culture when there 
was plenty of energy, apoptosis occurred and when the energy store was depleted, 
necrosis resulted (Leist et al, 1997).  Interestingly, apoptosis is found to initially occur in 
the core lesion in a model of cerebral infarction.  Necrosis dominates in the core or the 
initial lesion and apoptosis occurs in the penumbra or the expansion of the core where 
there are sufficient energy levels (Charriaut-Marlangue et al., 1996; Benchoua et al., 
2001). 
Additionally, there is evidence for a pattern of combined necrotic and apoptotic 
cell death (Wyllie and Golstein 2001; Sperandio et al., 2000; Martin et al., 1998; Leist 
and Jäättelä 2001; Nicotera et al., 1999; Fujikawa 2000a; Lee et al., 2000; Choi 1996; 
Choi 1995; Seo et al., 2009).  Ultrastructural studies showed hippocampal neurons died 
by necrosis 72 hours after induced-status epilepticus and global ischemia (Fujikawa et 
al.,1999; Colbourne et al., 2000; Fujikawa et al., 2000).  However, enzymatic studies 
showed that Tunel positive cells and caspase 3 activity colocalized together in 
hippocampal neurons 24 and 72 hours after induced-status epilepticus and ischemia 
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(Chen et al., 1998; Henshall et al., 2000; Kondratyev et al., 2000).  Finally there were 
studies that showed hippocampal injured neurons died by a caspase-dependent active 
form of necrosis after induced-status epilepticus.  The dying cells were morphologically 
necrotic but also had active caspase 3 located in the neurons (Niquet et al., 2007; Lopez-
Meraz et al., 2010b).  Sarin-induced seizures may initially cause apoptotic cell death but 
necrosis may take over if damage is too intense.  Since there is caspase activation in both 
apoptotic and necrotic death after status epilepticus induced seizures, a caspase inhibitor 
may prevent neuronal death in the hippocampus caused by sarin exposure.   
 
Broad Spectrum Caspase Inhibitor 
Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxyl]-methyl 
ketone) is a non-toxic, broad spectrum caspase inhibitor (Figure 7) that can prevent 
apoptosis by inhibiting the activation of all caspase pathways (Caserta et al, 2003) 
(Figure 8).  Q-VD-OPh specifically inhibits caspases.  It contains a quinoline group that 
protects the two amino acids, valine and aspartic acid, from degradation.  The OPh group 
eliminates in vivo toxicity and increases cell membrane permeability.  It is the most 
effective known caspase inhibitor that can cross the blood brain barrier and has been 
shown to be effective in numerous in vivo studies.  It reduced neuronal death and 
eliminated activated caspase 3 in the hippocampal neurons of rats with induced-status 
epilepticus (Lopez-Meraz et al., 2010a).  Q-VD-OPh has also been shown to decrease 
neuronal death in rats after neonatal stroke (Braun et al., 2007; Renolleau et al., 2007).  A 
caspase 3 inhibitor, z-DEVD-fmk, reduced neuronal death in the hippocampus of rats 
after induced-status epilepticus and ischemia (Chen et  
22 
 
Figure 7: Structure of Q-VD-OPh. 
The quinoline group is the protection group (A).  It contains two amino acids: 
valine (B) and aspartic acid (C).   The OPh group eliminates in vivo toxicity (D).  Q-VD-
OPh is specific for interacting with the pocket of caspases.   
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Figure 7 
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Figure 8: Q-VD-OPh inhibits caspases in the apoptotic pathway. 
 
Q-VD-OPh prevents the caspases 8/10, 9, and 3 from being activated. 
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Figure 8 
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al., 1998; Henshall et al., 2000; Kondratyev and Gale, 2000).  However, caspase 
inhibitors with a ‘fluoromethylketone (fmk)’ containing group have shown to be toxic in 
vivo due to the accumulation of fluoroacetate (Schotte et al., 1999; Van Noorden et al., 
2001; Caserta et al., 2003).  Since Q-VD-OPh has been shown effective at low 
concentrations, non-toxic to cells, and can cross the blood brain barrier (Caserta et al., 
2003), it is the preferred caspase inhibitor to use to prevent neuronal death in the brains 
of sarin-exposed mice.  
 
 Hypothesis and Aims 
Our overall hypothesis is that Q-VD-OPh will reduce or prevent caspase activated 
neuronal death in neurons of the hippocampus in sarin-exposed mice.  Reducing neuronal 
degeneration may help in preventing memory loss for those who are at a high risk of 
exposure to nerve agents.  The goal of the current work is to provide a negative control 
and to optimize protocols to analyze neuronal death in sarin-exposed mice treated with 
Q-VD-OPh. 
Before Q-VD-OPh effectiveness in preventing neuronal death in sarin-exposed 
mice can be evaluated, we needed to design a negative control.  The caspase inhibitor, Q-
VE-OPh, was synthesized as an equivalent dipeptide amino acid analog similar to the 
broad-spectrum caspase inhibitor, Q-VD-OPh (Southerland et al., 2010).  It includes the 
addition of a single carbon element to the aspartic acid (D) residue changing it to 
glutamic acid (E). 
The current negative control for caspase inhibitors is Z-FA-fmk (Z- 
Phenylalanine-Alanine-fluoromethylketone).  This does not represent a true negative 
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control for caspase inhibitors because it inhibits effector caspases and cathepsin B 
(Lopez-Hernandez et al., 2003; Lawerence et al., 2006; Gezginci-Oktayoglu et al., 2008).  
Q-VE-OPh would be a better negative control than Z-FA-fmk, because it has similar 
features to Q-VD-OPh. 
Sarin-exposed mouse brains treated with Q-VD-OPh or Q-VE-OPh will be 
analyzed by immunohistochemistry.  Tunel assay will detect cell death after sarin 
exposure.  Neuronal neuron (NeuN) will detect neurons in the brain to show where cell 
death occurs in the brain after sarin exposure.  Because sarin is restricted by the US 
Department of Defense to being used in two places in the United States, all of our 
experiments must be done at one time and at the same facility. 
Therefore, before we proceed in analyzing sarin-exposed brain sections, it is 
critical to optimize brain tissue processing techniques, storage conditions, and the 
immunohistochemistry assays in untreated mice as indicated below.  
 
Aim 1 
To determine if the caspase inhibitor, Q-VE-OPh, can be used as a negative control for 
O-phenoxy-conjugated caspase inhibitors. 
Aim 2 
To optimize brain processing techniques and storage conditions in mice not exposed to 
sarin. 
Aim 3 
To optimize Tunel assay and NeuN staining by eliminating background and obtaining 
optimal contrast between stain and background. 
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II. MATERIALS AND METHODS 
Materials 
Jurkat T cells (clone E6-1) were obtained from ATCC.  Caspase 8 antibody was 
purchased from Cell Signaling, Inc and caspase 9 antibody was purchased from Santa 
Cruz Biotechnology. Actinomycin D was obtained from Calbiochem, Inc. Immobilon P 
was purchased from Millipore. Supersignal chemiluminescence reagent was purchased 
from Pierce, Inc.  Tunel assay was completed by using the NeuroTACS II In Situ 
Apoptosis Detection Kit (Trevigen).  Avidin-Biotin Conjugate (ABC) was received from 
Vector Laboratories.  Anti-NeuN was acquired from Millipore Cat #: MAB377.  Anti-
mouse biotinylated antibody was bought from Vector Labortories, Cat #: BA-9200.  
 
Production of Q-VD-OPh and Q-VE-OPh 
The caspase inhibitor Q-VD-OPh and corresponding negative control Q-VE-OPh 
were produced by Apoptrol, LLC (Caserta et al., 2003; Southerland et al., 2010). Briefly, 
amino terminally- protected aspartyl or glutamyl groups were converted to—OPh 
conjugates and then reacted to elicit the methylated forms of Q-VD (OMe)-OPh and Q-
VE(OMe)-OPh (Caserta et al., 2003; Southerland et al., 2010). This was followed by 
HPLC purification.  Production of the non-methylated compounds was achieved by 
saponification. Q-VD-OPh and Q-VE-OPh were solubilized in DMSO prior to use. 
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Cell Culture 
Jurkat human T cells were cultured at 1 × 10
6
 cells/ml, unless otherwise indicated, in 
RPMI 1640 containing 10% FBS and antibiotic/antimycotic.  All cells were cultured at 
37°C and 95% O2 / 5% CO2. 
 
Apoptotic DNA Ladder Assays 
Jurkat cells (1 × 10
6
 cells/ml) in 10 mls were preincubated 30 minutes with 
vehicle, drug alone, or various concentrations of Q-VE-OPh or Q-VD-OPh, prior to 
treatment with actinomycin D for 4 hrs. Cytoplasmic DNA was isolated and analyzed for 
DNA laddering.  Briefly, apoptosis was measured by analysis of an oligonucleosomal 
DNA ladder in agarose gels as previously reported (Brown et al., 1998; Brown et al., 
1999; Brown et al., 2000; Caserta et al., 2003).
 
 Cells (1 × 10
7
) were centrifuged at 1,000 
rpm for 5 min and lysed in HL buffer for 15 min. The lysate was extracted with an equal 
volume of phenol, and then phenol:chloroform:isoamyl alcohol (25:24:1), and 
precipitated 18 h at −20°C with an equal volume of isopropanol and 0.1 volume of 5 M 
NaCl. The precipitated DNA was resuspended in Tris/EDTA, pH 8.0, containing DNase-
free RNase A and incubated at 37°C for 30 min. The DNA was analyzed on a 1.2% 
agarose gel containing ethidium bromide. 
 
Western Blot 
Protein concentrations and Western blotting were performed as described 
previously (Brown et al., 1999; Brown et al., 2000; Patil et al., 2000; Caserta et al., 
2003).  Briefly, 100 μg of whole cell lysate was separated by SDS-PAGE and transferred 
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to Immobilon-P polyvinylidene difluoride membrane. Protein transfer was empirically 
determined by staining with 1.0% Ponceau S. following transfer (Brown et al., 1999; 
Brown et al., 2000; Caserta et al., 2003).  The membrane was incubated in blocking 
buffer (60 mM Tris, 200 mM NaCl with 0.05% Tween 20 containing 5% nonfat dry milk, 
pH 7.4) and incubated with a 1:1,000 dilution of primary antibody for 2 h at room 
temperature. The blot was washed and then incubated with a 1:50,000 dilution of goat 
anti-rabbit horseradish peroxidase secondary antibody for 1 h at room temperature and 
processed using the Supersignal chemiluminescence reagent according to manufacturer’s 
instructions. 
 
Cell Proliferation and Viability Assay 
Jurkat human T cells (1 × 10
5
 cells/ml) were treated for 72 hrs with vehicle (V), 
cell death inducer 1 μg/ml actinomycin D, 100 μM Q-VD-OPh or 100 μM Q-VE-OPh.  
Cell viability was determined by cell count and trypan blue staining at 24 hr intervals. 
 
Tissue Collection and Sectioning 
All animal studies were in accordance with policies and procedures of the 
laboratory animal care and use committee.  Mice were sacrificed by decapitation after 
CO2 incapacitation and brain tissue was collected for histology.  Whole brains were quick 
frozen in isopentane for 20 seconds and then stored at -80°C until sectioning.  Brain 
tissue was mounted, covered with OCT Embedding Compound, and coronally sliced on a 
cryotome (at approx. -24°C) at 10μm thickness.  Sections were collected on Superfrost 
Plus Microscope slides, dried overnight at room temperature, rehydrated in ethanol series 
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(100%, 95%, and 70%) for 5 minutes each respectively, fixed in 4% paraformaldehyde 
for 10 minutes, and either stored or stained.  Slides were stored at -80°C after fixation 
until needed for staining. 
 
Hematoxylin and Eosin Staining 
Slides were sequentially dipped in the following solutions: hematoxylin for 2 
minutes, running tap water for 2 minutes, 50% ethanol for 2 minutes, 70% ethanol for 2 
minutes, eosin for 15 secs, 95% ethanol for 1 min, 100% ethanol twice for 2 minutes, and 
xylene twice for 2 minutes.  Slides were coverslipped and mounted in permount. 
 
Diaminobenzidine (DAB) Stain 
Sections were blocked in a 6% hydrogen peroxide solution in methanol for 10 
minutes.  In some cases, an additional avidin-biotin block was used after 6% hydrogen 
peroxide block, where avidin solution was first used for 15 minutes, followed by a biotin 
solution for 15 minutes.  Slides were then washed 4 times in 1 x phosphate buffer saline 
(1x PBS) for 2 minutes each after each solution was applied to sections.  Avidin-Biotin 
Conjugate (ABC) solution was applied to slides that contained the additional avidin and 
biotin block for 1.5 hours.  All slides were then immersed in DAB solution for 4 minutes 
followed by 4 washes in double distilled water for 2 minutes each.  Slides were immersed 
in a blue counterstain for 2 minutes and then dipped 10 times into 70% ethanol, 95% 
ethanol, 100% ethanol, and xylene respectively (2 changes each).  Sections were 
coverslipped and mounted using clearmount medium. 
 
32 
 
Terminal deoxynucleotidyl transferase-mediated biotinylated UTP Nick End Labeling 
(TUNEL) 
TUNEL staining was performed on brain sections using the NeuroTACS II In Situ 
Apoptosis Detection Kit.  The following modifications were made to the assay protocol 
to improve the contrast of stains and to decrease background.  The quenching solution 
was increased from 3% hydrogen peroxide to 6% hydrogen peroxide for 10 minutes to 
better block endogenous peroxidase in the brain.  Slides were immersed in DAB solution 
for 4 minutes.  Washes after the quenching solution step were increased to 4 washes for 3 
minutes.  Two washes of 1% bovine albumin serum (BSA) and 0.05% tween in 1x PBS 
for 2 minutes were added after the Strepavidin-HRP step followed by 2 additional 1x 
PBS washes for 2 minutes.  Washes after the DAB stain were followed by the protocol.  
Sections were mounted using clearmount medium. 
 
NeuN Immunohistochemsitry 
Slides were fixed in 4% paraformaldehyde in 1x PBS and 0.1% trition solution 
(1x PBS/T) for 10 minutes.  An antigen retrieval step was performed using 1x citrate 
buffer and boiled for 10 minutes.  Sections were then washed 3 times for 5 minutes in (1x 
PBS/T) and blocked in 10% normal goat serum for 30 minutes.  An addition, sections 
were blocked using 6% hydrogen peroxide in methanol followed by an avidin-biotin 
block for 15 minutes.  Slides were washed 4 times in 1x PBS for 3 minutes after each 
blocking step.  Sections were labeled with 1:100 anti-NeuN in 1x PBS overnight at 4°C 
and then washed as previously described.  Secondary antibody was applied at 1:1000 
anti-mouse biotinylated made in goat in 1x PBS/T for 1.5 hours at 4°C and then washed.  
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Avidin-Biotin Conjugate was applied to sections for 1 hour and washed in 1% BSA and 
0.05% tween in 1x PBS twice for 3 minutes followed by 2 additional washes in 1x PBS 
for 3 minutes. Sections were then labeled with DAB and washed 4 times for 2 minutes in 
double distilled water.  Slides were immersed in a blue counterstain for 2 minutes and 
then dipped 10 times into 70% ethanol, 95% ethanol, 100% ethanol, and xylene 
respectively (2 changes each).  Sections were mounted using clearmount medium. 
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III. RESULTS 
Q-VE-OPh, a negative control 
In order to validate Q-VD-OPh effectiveness in preventing neuronal death in 
sarin-exposed mice, we needed to develop an appropriate negative control.  Knowing that 
the aspartic acid residue on Q-VD-OPh is crucial for inhibition, the caspase inhibitor 
analog Q-VE-OPh was synthesized as an equivalent dipeptide amino acid analog similar 
to the broad-spectrum caspase inhibitor, Q-VD-OPh.  The aspartic acid (D) in Q-VD-OPh 
was replaced with glutamic acid (E) to generate a nearly identical compund, Q-VE-OPh 
(Figure 9). 
To determine the ability of Q-VE-OPh to inhibit apoptosis, Jurkat T leukemia 
cells were first treated with Q-VE-OPh followed by actinomycin D for 4 hours and 
analyzed by DNA ladder assay (Figure 10).  Actinomycin D alone induced substantial 
apoptosis after 4 hours, as determined by the presence of a classic DNA ladder.  
Incubation with vehicle, Q-VD-OPh, or Q-VE-OPh alone did not induce apoptosis.  Pre-
incubation with Q-VD-OPh for 30 minutes followed by 4 hours of actinomycin D 
treatment prevented DNA laddering as low as 5μM of Q-VD-OPh.  In contrast, Q-VE-
OPh co-incubation with actinomycin D did not prevent DNA laddering in the effective 5-
20μM range for Q-VD-OPh.  Partial DNA ladder inhibition was observed at 100 μM of 
Q-VE-OPh.  This indicates that Q-VE-OPh is at least 20 times less effective at inhibiting 
apoptosis than the caspase inhibitor Q-VD-OPh.  Apoptosis is dependent upon caspase  
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Figure 9: Chemical structure of Q-VE-OPh and Q-VD-OPh. 
The aspartic acid (D) in Q-VD-OPh was replaced to glutamic acid (E) to generate 
the negative control, Q-VE-OPh. 
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Figure 9 
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Figure 10: Q-VD-OPh and Q-VE-OPh effects on apoptotic DNA laddering in Jurkat 
Cells. 
Jurkat cells (1 x 10
6
 cells/ml) were treated for 4 hrs with vehicle (V), 1μg/ml 
actinomycin D (AD), drug alone 100μM (D), or various concentrations (1, 5, 10, 20, 50, 
or 100μM) of Q-VE-OPh (A) or Q-VD-OPh (B); preincubated 30 mins, prior to 
actinomycin D addition.  DNA was analyzed by isolation and evaluation of cytosolic 
DNA on a 1.2% agarose gel.  (M) indicates a Hi Lo DNA molecular weight marker.  
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Figure 10 
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activation which is dependent on the cleavage of specific caspase enzymes.  To further 
confirm the inability of Q-VE-OPh to inhibit caspase activation at relevant 
concentrations, human initiator caspases 8 and 9 activation were analyzed by Western 
blot analysis (Figure 11).  Pro-caspase 8 and pro-caspase 9 were present in vehicle or Q-
VD-OPh or Q-VE-OPh alone.  Actinomycin D cleaved caspase 8 and 9 and therefore 
activated the apoptosis pathway.  Co-treated cells with Q-VD-OPh and actinomycin D 
prevented cleaved-caspase 8 and cleaved-caspase 9.  However, co-treated cells with Q-
VE-OPh and actinomycin D did not prevent cleaved-caspase 8 and cleaved-caspase 9.  
Therefore, Q-VD-OPh inhibited cleavage and activation of caspase 8 and 9, whereas Q-
VE-OPh did not.  The Western blot results confirm our DNA ladder findings that Q-VE-
OPh is a superior cognate negative control for Q-VD-OPh and O-Phenoxy caspase 
inhibitor studies; when used within the correct and recommended concentration ranges. 
Q-VD-OPh has previously been shown to be nontoxic (Caserta et al., 2003).  To 
determine if Q-VE-OPh was also nontoxic, cells were treated with Q-VE-OPh for 72 
hours and cell viability was assessed (Figure 12).  As anticipated, Q-VE-OPh 
demonstrated no signs of toxicity and allowed undisrupted cell proliferation to occur over 
the entire time course evaluated. 
 
Immunohistochemistry optimizations 
In order to analyze brains by immunohistochemistry, we first optimized brain 
processing techniques of untreated mice using a hematoxylin and eosin (H&E) stain.  
Drying the brain tissue overnight at room temperature after sectioning but before  
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Figure 11: Western blot analysis on cleaved and activated caspase 8 and 9. 
 
Q-VE-OPh does not prevent initiator caspase 8 or caspase 9 activation. Jurkat 
human T cells (1 × 10
6
 cells/ml) were treated for 4 hrs with vehicle (V), 1 μg/ml 
actinomycin D (AD), 20 μM Q-VD-OPh (QVD), 20 μM Q-VD-OPh preincubated 1 hr 
prior to addition of 1 μg/ml actinomycin D (QVD + AD), 20 μM Q-VE-OPh (QVE), 20 
μM Q-VE-OPh, preincubated 1 hr prior to addition of 1 μg/ml actinomycin D (QVE + 
AD). 100 μg of whole cell lysate was separated by SDS-PAGE and Western blotting was 
performed using rabbit polyclonal antibody to caspase 8 (A) and caspase 9 (B), and 
developed using Supersignal chemiluminesence. Arrows indicate the molecular weights 
of the inactive proforms as well as the cleaved and activated forms of caspase 8 and 9. 
Faint cleavage fragments seen in the vehicle and Q-VE-OPh lanes in (A) are due to a low 
level of background apoptosis. Equal protein loading was present in all lanes (data not 
shown). 
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Figure 11 
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Figure 12: Percent viability on Jurkat T leukemia cells treated with vehicle, Q-VD-
OPh, Q-VE-OPh, or Actinomycin D. 
Q-VE-OPh is not toxic. Jurkat human T cells (1 × 10
5
 cells/ml) were treated for 
72 hrs with vehicle (V), 1 μg/ml actinomycin D (AD), 100 μM Q-VD-OPh (QVD) or 100 
μM Q-VE-OPh. Cell viability was determined by trypan blue staining of cells at 24 hr 
intervals. 
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Figure 12 
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fixation and staining was critical in order to preserve the quality of the tissue (Figure 13).  
The brain contains cerebrospinal fluid and therefore is critical to dry the tissue section out 
thoroughly to prevent water from separating the tissue.  Drying allows the tissue to 
properly expand and has a better morphological appearance. 
In vivo sarin experiments will be performed by MRI Global, Kansas City, MO.  
Brains will be sectioned and placed on slides to be sent to us.  Not all sarin slides will be 
analyzed in one day and will need to be stored in the -80°C.  Therefore we need to 
determine the best way to handle slides when taking them out of the freezer.  Mouse 
brains will be sectioned, dried overnight, fixed, and then stored in the -80°C.  To 
determine if slides need to be redried and/or the amount of time slides should dry after 
storage, we used a DAB stain to examine background and an H&E stain to look at tissue 
quality.  Storing slides did not create any background issues or freezer burn when either 
redried overnight at room temperature, redried for 2 hours at room temperature, or not 
drying at all (Figure 14).  Slides should be stored in a slide holding box that is in a freezer 
bag to prevent freezer burn (data not shown).  An H&E stain showed that it is necessary 
to redry slides overnight at room temperature to prevent holes in the tissue (Figure 15).  
Holes in the tissue from not properly drying slides from the freezer could appear as 
artifacts in sarin treated sections. 
Next, we optimized Tunel assay and NeuN staining in untreated mice by 
decreasing background and increasing contrast between the stain and the background.  
Tunel assay works by detecting cell death in both apoptotic and necrotic cells.  In order to 
label cell death in untreated mice, a nuclease was used to fragment the DNA as a positive 
control.  The labeling procedure includes using a terminal deoxynucleotidyl  
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Figure 13: Optimizing brain processing techniques by Hematoxylin and Eosin Stain 
 
The order of sectioning, drying, fixing, and staining were varied.  Brain tissue was 
sectioned, fixed, and stained (A).  Brain tissue was sectioned, fixed, dried overnight, and 
stained (B).  Brain tissue was sectioned, dried overnight, fixed, and stained (C). 
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Figure 13 
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Figure 14: DAB stain on stored slides in -80°C freezer. 
 
 Slides were sectioned, dried overnight at room temperature, fixed, and stored in 
the -80°C freezer for two weeks.  Slides were taken out of the -80°C freezer and were 
either redried overnight at room temperature, dried for 2 hours at room temperature, or 
not dried.  Sections were blocked in 6% H2O2 for 10 mins and labeled with DAB. 
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Figure 14 
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Figure 15: H&E stain on stored slides in -80°C freezer. 
 
 Slides were sectioned, dried overnight at room temperature, fixed, and stored in 
the -80°C freezer for two weeks.  Slides were taken out of the -80°C freezer and were 
either redried overnight at room temperature, dried for 2 hours at room temperature, or 
not dried.  Sections were stained with hematoxylin and eosin 
. 
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Figure 15 
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transferase (TdT) to transfer a deoxynucleotide triphosphate (dNTP) molecule connected 
to biotin on to the ends of DNA breaks, then adding a strepavidin-horse radish peroxidase 
(HRP) to biotin, and finally labeling the DNA breaks by immersing the slides into a 
diaminobenzidine (DAB) solution.  The HRP will oxidize DAB, thereby labeling DNA 
breaks in the cell brown (Figure 16).  Elimination of Tdt (-Tdt) in the Tunel assay serves 
as a negative control for background staining.  NeuN staining works by using a 
monoclonal primary antibody that stains the nuclei and cytoplasm of most neuronal cell 
types in all regions of the adult brain (Mullen et al., 1992).  A biotinylated secondary is 
used to recognize the primary antibody.  Next, an avidin-biotin conjugate (ABC) is used 
to bind to the biotin of the secondary.  The biotin has HRP attached to it so that DAB can 
label neurons brown (Figure 17). 
To prevent false labeling in both Tunel assay and NeuN staining, we had to block 
endogenous peroxidase (Yamaguchi and Eto, 1983).  First we determined an optimal 
concentration and timing for a peroxidase blocker using DAB solution on sections only.  
3% hydrogen peroxide (H2O2) was used at 0, 3, 5, 10, 15, 30, and 45 minutes to quench 
endogenous peroxidase in brain sections.  The optimal time to prevent peroxidase using 
3% H2O2 was 45 minutes (Figure 18).  We also used 6% H2O2 at 0, 3, 5, 10, 15, 30, and 
45 minutes and found 10 minutes of 6% H2O2 was optimal at this concentration (Figure 
19).  In comparing no block, 3% H2O2 for 45 minutes, and 6% H2O2 at 10 minutes, we 
observed that 6% H2O2 for 10 minutes eliminated peroxidase activity the best and used it 
in all future stainings (Figure 20).   
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Figure 16: Tunel Assay 
 
 Tunel assay detects cell death in necrotic or apoptotic cells.  A nuclease is used to 
fragment the DNA to optimize labeling in untreated mice.  The labeling procedure 
includes using a terminal deoxynucleotidyl transferase (TdT) to transfer a 
deoxynucleotide triphosphate (dNTP) molecule connected to biotin on to the ends of 
DNA breaks (A), then adding a strepavidin-horse radish peroxidase (HRP) to biotin (B), 
and finally labeling the DNA breaks by immersing the slides into a diaminobenzidine 
(DAB) solution (C). 
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Modified from the protocol in NeuroTACS II In Situ Apoptosis Detection Kit. 
Figure 16 
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Figure 17: NeuN Staining 
 Neurons were labeled using anti-NeuN primary antibody (A).  The biotinylated 
secondary, anti-mouse, was used to bind the primary antibody (B).  Next, an avidin-biotin 
conjugate (ABC) attached to the biotin of the secondary (C).  The biotin has HRP (D) 
connected to it so that DAB (E) can label neurons brown. 
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Figure 17 
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Figure 18: 3% H2O2 Block 
 
Slides were blocked in 3% hydrogen peroxide (H2O2) for 0, 3, 5, 10, 15, 30, and 
45 mins to quench endogenous peroxidase in brain sections and labeled using DAB. 
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Figure 18 
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Figure 19: 6% H2O2 Block 
 
Slides were blocked in 6% hydrogen peroxide (H2O2) for 0, 3, 5, 10, 15, 30, and 
45 mins to quench endogenous peroxidase in brain sections and labeled using DAB. 
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Figure 19 
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Figure 20: Optimal peroxidase block 
  Compares the optimal block between no block, 3% H2O2 block for 45 mins, or 
6% H2O2 block for 10mins.  Sections labeled using DAB. 
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Figure 20 
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We also had to block endogenous biotin found in the brain (Zempleni et al., 2009) 
for NeuN staining by using an avidin-biotin blocker.  To determine optimal timing of 
avidin-biotin blocking, we used an avidin-biotin blocker, ABC, and DAB solution.   
Avidin-biotin blocker was used for 0, 5, 15, and 30 minutes.  At 15 minutes, the avidin-
biotin blocker eliminated labeling of endogenous biotin (Figure 21). 
DAB timing was optimized to create maximum contrast between the staining of 
the nuclei and the background.  Tunel assay was performed and DAB times were varied 
from 0-7 minutes.  At 4 minutes there was enough contrast to distinguish the brown 
staining of DNA fragments in the nuclei (Figure 22).  DAB time of 4 minutes can also be 
used for NeuN staining. 
To further eliminate background in Tunel assay and NeuN staining, we rinsed off 
labeling residue by using 1% bovine serum albumin (BSA) and 0.05% tween wash (BSA-
T) after the strep-avidin HRP or ABC labeling step.  BSA stabilizes enzymes and tween 
is a detergent.  In both positive and negative controls, BSA-T rinsed off any additional 
residue from the labeling steps on the brain section (Figure 23).  In addition to a BSA-T 
wash, the number of washes after each blocking step and labeling step is important.  
Using a 3% H2O2 for 5 minutes and a DAB label, we found it was necessary to wash 
slides 4 times in 1x PBS after the peroxidase blocking step to rinse off extra hydrogen 
peroxide (Figure 24). 
The CA1, CA2, CA3, and dentate gyrus of the hippocampus are the main regions 
sarin could cause neuronal death in mouse brain, therefore our Tunel assay pictures will 
be of the hippocampus (Paxinos and Franklin, 2001)(Figure 25). In order to decrease 
background in Tunel assay of the mouse brain, we made several modifications to the  
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Figure 21: Avidin-Biotin Block 
 
Slides were blocked in 6% H2O2 for 10 mins, avidin-biotin block for 0, 5, 15, and 
30mins to quench endogenous biotoin in brain sections and labeled using avidin-biotin 
conjugate (ABC) and DAB. 
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Figure 21 
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Figure 22: Optimization of DAB timing in Tunel assay 
Sections were blocked using 6% H2O2 for 10 mins, avidin-biotin block for 15 
mins, and labeled with DAB for 0, 0.5, 1, 4, or 7 mins. 
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Figure 22 
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Figure 23: Bovine Serum Albumin and Tween (BSA-T) Wash 
 
 Sections were washed twice in 1% BSA and 0.05% tween for 3 mins after the 
strepavidin-HRP step of the Tunel assay in both positive (+ nuclease) and negative (- Tdt) 
controls.  Sections were washed two additional times in 1x PBS. 
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Figure 23 
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Figure 24: Washes in 1x PBS 
 
 Sections were blocked using 3% H2O2 for 10 mins, washed 0, 1, 2, or 3 times with 
1x PBS, and labeled with DAB for 4 mins.   
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Figure 24 
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Figure 25: Hippocampus of mouse brain 
The outer box represents a section of the mouse brain that contains the 
hippocampus.  The inset outlines the hippocampus which is the main region of the brain 
where neuronal death is found after sarin exposure.  The hippocampus consists of the 
CA1, CA2, CA3, and dentate gyrus (DG) regions. 
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Figure 25 
 
Paxinos G and Franklin K.  The mouse brain in stereotaxic coordinates.  2
nd
 ed.  San 
Diego, Calif: Academic.  2001. 
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NeuroTACS II In Situ Apoptosis Detection Kit’s Tunel assay protocol: 1. Increased 
hydrogen peroxide block from 3% for 5 minutes to 6% for 10 minutes.  2.  Increased 
washes from 1 wash of 1x PBS for 2 minutes to 4 washes of 1x PBS for 3 minutes after 
each blocking and labeling step.  3.  Added two 1% BSA and 0.05% tween wash steps 
after the strepavidin-HRP labeling step for 3 minutes followed by two additional washes 
in 1x PBS.  4.  Determined that sections needed to be stained with DAB for 4 minutes to 
created optimal contrast between brown stain of nuclei to the background.  Background 
on Tunel assay on mouse brain dramatically decreased after these modifications (Figure 
26).  A close up of the Tunel assay of the CA1 region of the hippocampus shows good 
contrast between the brown labeling of fragmented DNA and the other cells (Figure 27). 
In our sarin experiments, we will show that neurons of the hippocampus die in 
sarin treated mice.  We developed a protocol for NeuN staining in mouse brain by 
making modifications to the suggested protocol that included the same modifications as 
the Tunel assay and an additional 15 minutes avidin-biotin block.  Neurons were detected 
in mouse brains not treated with sarin (Figure 28). 
 
 
 
 
 
 
 
82 
 
Figure 26: Tunel assay before and after modifications 
Background decreases in Tunel assay after modifications are made to the 
NeuroTACS II In Situ Apoptosis Detection Kit’s protocol.  Pictures are shown of both 
positive and negative controls before modifications (A) and after modifications (B).  
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Figure 26 
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Figure 27: Tunel assay of the CA1 region 
 Both positive and negative control pictures of Tunel assay of the CA1 region of 
the hippocampus in mouse brain at 40X. 
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Figure 27 
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Figure 28: NeuN Staining 
Neurons were labeled brown by DAB in untreated mouse brains. 
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Figure 28 
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IV. DISCUSSION 
Q-VE-OPh was designed to identify and characterize an analog of the widely used 
in vivo, broad-spectrum caspase inhibitor, Q-VD-OPh.  In order to create this analog, the 
aspartic acid residue on Q-VD-OPh was replaced with a glutamic acid residue.  The only 
difference between the two molecules is that Q-VE-OPh has the addition of a single 
carbon ion on the aspartic acid residue of Q-VD-OPh.  Therefore Q-VE-OPh is nearly 
identical due to the same charge and similar mass (data not shown).  It was anticipated 
that this small addition would change Q-VE-OPh’s effectiveness as a caspase inhibitor in 
cell culture.  Q-VE-OPh was unable to inhibit DNA fragmentation or caspase activation 
at relevant concentrations.  This implies that the specificity of Q-VD-OPh binding pocket 
to caspases is high and that a single addition of a carbon is enough to alter its binding 
capabilities.  Based on the concentrations, Q-VE-OPh was 20 times less effective than Q-
VD-OPh, which provides it as an optimal negative control at effective concentrations.  
Furthermore, Q-VE-OPh is not toxic over time.  Q-VD-OPh has been widely used in vivo 
for extended periods of time and is recommended for use due to its lack of toxicity.  It is 
likely that the –OPh moiety eliminates in vivo toxicity and that the use of Q-VE-OPh as a 
negative control for caspase inhibitors in vivo will also have no associated toxicity. 
The current negative control for caspase inhibitors is Z-FA-fmk (Z- 
Phenylalanine-Alanine-fluro methyl ketone).  Surprisingly, this does not represent a true 
negative control for caspase inhibitors because it inhibits effector caspases which will 
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lead to preventing apoptosis (Lopez-Hernandez et al., 2003; Gezginci-Oktayoglu et al., 
2008).  It is also not specific towards caspases in cell death since it also inhibits cathepsin 
B, which is a lysosomal cysteine protease (Lawerence et al., 2006).  In addition to it 
being a poor negative control, its use in vivo is not reasonable because of its toxicity due 
to the accumulation of fluoroacetate (Eichhold et al., 1997; Van Noorden 2001; Caserta 
et al., 2003).   
In conclusion, we have produced and determined the effectiveness of a novel and 
appropriate negative control, Q-VE-OPh, for the broad-spectrum caspase inhibitor Q-
VD-OPh (Southerland et al., 2010).  It provides a new and useful tool to confirm the 
specificity of O-phenoxy caspase inihibitors when studying mammalian apoptosis both in 
vitro and in vivo. 
Q-VE-OPh will serve as a negative control in experiments where mice are 
exposed to sarin.  Mice will be injected with sarin and treated with Q-VD-OPh or Q-VE-
OPh 30 minutes post sarin and their brain tissue will be collected 2 and 14 days later for 
immunohistochemistry analysis.  Neuronal death is expected to be found at day 2, 
whereas inflammation is expected to be highest at day 14.  We will analyze these days to 
see if Q-VD-OPh decreases neuronal death and inflammation. 
Our studies showed that Q-VD-OPh can prevent apoptosis when given 30 minutes 
prior to being induced to die apoptotically with actinomycin D.  However, in a situation 
when a person is exposed to sarin, Q-VD-OPh would be injected after sarin exposure.  In 
cells, Q-VD-OPh can be given 30 minutes after treatment with actinomycin D to prevent 
apoptosis (data not shown).  After that time period, Q-VD-OPh will not be able to 
prevent apoptosis because certain events would have taken place late in the apoptotic 
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pathway.  Therefore, in a real situation of being exposed to sarin, one would need to take 
Q-VD-OPh shortly after being exposed in order to prevent neuronal damage in the brain. 
Since sarin’s use in experimental applications is highly restricted and regulated by 
the US Department of Defense, it can only be used in two places in the United States.  
Therefore, it is first critical to optimize each assay in untreated mice or mice not exposed 
to sarin before proceeding with experimental slides. 
We optimized mouse brain processing techniques, storage conditions, and the 
immunohistochemistry assays in untreated mouse brain.  The quality of the stains is 
affected if the brain tissue has not been properly dried out.  Since the brain has a high 
fluid content from the cerebrospinal fluid, we found it critical to let the brain sections sit 
out overnight at room temperature to thoroughly dry the tissue.  Drying the tissue will 
enhance morphological appearance of stains.  We also found that it is best to redry the 
brain sections overnight at room temperature after storing in the -80°C freezer.  The 
sections have water on them from being out in the open and when stored in the freezer, 
the water will form ice crystals.  When slides are removed from the -80°C freezer, they 
need to be returned to room temperature and redried in order to prevent holes in the 
tissue.  Sarin causes lesions in the brain, thus these holes may be artifacts in sarin treated 
mice brains if sections are not thoroughly dried. 
In our immunohistochemistry analysis, we will detect neuronal death in the brains 
of sarin-exposed mice treated with Q-VD-OPh or Q-VE-OPh by doing a Tunel assay.  
Tunel assay labels DNA double stranded breaks in the cells brown due to the 
diaminobenzidine (DAB) label.  DAB will be turned brown after being oxidized by 
strepavidin-HRP from the Tunel assay labeling procedure as well as from endogenous 
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peroxidase in the brain (Yamaguchi and Eto, 1983).  Therefore, a peroxidase blocker is 
needed to prevent false labeling of neuronal death.  Hydrogen peroxide treatment on 
brain sections will quench any peroxidase activity.  The generic protocol from the 
NeuroTACS II In Situ Apoptosis Detection Kit suggested a 3% H2O2 in methanol for a 5 
minute treatment to block peroxidase activity in tissues.  We determined that an increase 
from 3% H2O2 to 6% H2O2 solution in methanol for 10 minutes is necessary to block 
peroxidase activity in brain tissue.  Too much hydrogen peroxide could cause DNA 
damage in cells and create false Tunel positive cells (Stadelmann and Lassmann, 2000).  
There were no additional Tunel positive cells in our sections that showed untreated cell 
death in the brain between 3% H2O2 and 6% H2O2 blocks (data not shown).  This implies 
that increasing the hydrogen peroxide concentration to 6% for 10 minutes did not 
produce any false Tunel positive cells.  Furthermore, washing off additional blocking or 
labeling residue from the sections is important to eliminate background in stains.  
NeuroTACS II In Situ Apoptosis Detection Kit protocol suggest one wash after the 
hydrogen peroxide blocking step.  We determined that 4 washes of 1x PBS are necessary 
to rinse off all extra blocking or labeling residue.  In addition, two washes of 1% bovine 
serum albumin (BSA) and 0.05% tween (BSA-T) for 3 minutes each after the strep-
avidin HRP labeling step will aide in further rinsing off any extra labeling residue.  This 
decreases the background staining to have a cleaner Tunel assay.  One other Tunel assay 
optimization was to determine the amount of time DAB should be on sections to label 
DNA breaks in cells.  Four minutes of immersing slides into a DAB solution was optimal 
to clearly observe cell death in brain tissue.   
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Tunel assay detects in situ DNA fragmentation of both apoptotic and necrotic cell 
death (Gavrieli et al., 1992; Stadelmann and Lassmann, 2000).  Sarin-induced seizures 
can cause both apoptosis and necrosis.  DNA fragmentation during apoptosis is induced 
by caspase-mediated cleavage of caspase-activated DNase which produces the 
characteristic internucleosomal DNA double strand breaks of 180-200 base pairs and can 
be detected by dark brown staining of the nuclei in Tunel assay.  However, other 
fragments of 50-150 base pairs are also generated that lack the prototypical 
internucleosomal pattern of DNA fragmentation, such as in necrotic cell death.  It is 
worth noting that Tunel positive cells that are necrotic may appear to have a lighter stain 
because of the smaller fragments throughout the cell (Stadelmann and Lassmann, 2000).   
Further immunohistochemistry analysis includes detecting damage neurons in 
sarin-exposed mice by labeling neurons with NeuN.  The same 6% H2O2 block used in 
the Tunel assay will be used for the NeuN staining to prevent false labeling of neurons 
since a DAB stain is used.  In addition to a peroxidase block, a biotin blocker is needed 
for the NeuN staining, whereas it is not needed for the Tunel assay.  Biotin is a vitamin 
essential for metabolism and is widely distributed in the body (Dakshinamurti and 
Chauhan, 1989).  The CA3 and CA4 regions of the hippocampus were specifically found 
to be positive for endogenous biotin (Wang and Pevsner, 1999).  The avidin-biotin 
conjugate (ABC) will bind to biotinylated secondary antibody and also endogenous biotin 
in the brain (Zempleni et al., 2009).  We found it necessary to use an avidin-biotin 
blocker for 15 minutes to block endogenous biotin in a DAB stain.  The same washing 
optimizations and DAB timing used in the Tunel assay will be used for NeuN staining. 
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In future studies, mice will be injected with sarin and then treated with Q-VD-
OPh or Q-VE-OPh 30 minutes post sarin and brains will be collected 2 and 14 days for 
immunohistochemistry analysis.  In our immunohistochemistry analysis, we will 
demonstrate by Tunel assay that cell death occurs in sarin-exposed mice and that cell 
death is decreased or eliminated in Q-VD-OPh treated sarin-exposed mice by Tunel 
assay.  Second, we will illustrate that cell death is found in neurons by labeling the cells 
with a neuronal neuron antibody (NeuN).  Third we will confirm that neuronal death is 
activated by caspases by the detection of caspase 3 antibody.  We expect to see a 
decrease in neuronal death and in caspase 3 activation in sarin-exposed mice treated with 
Q-VD-OPh compared to sarin-exposed mice treated with Q-VE-OPh. 
The type of mice chosen is very important.  Factors to take into consideration are 
the age and gender of the mice.  The stage of maturity the brain is in can affect whether 
death occurs by apoptosis or necrosis. The apoptotic pathway was shown to occur in an 
immature region of the brain in neonatal mice (Lopez-Meraz et al., 2010b).  Thus, Q-VD-
OPh may work better in neonatal mice.  However, people who are likely to be exposed to 
a nerve agent will be adults, it is necessary to use adult mice.  Gender may be an issue 
because one study showed a decrease in cell death in Q-VD-OPh treated postnatal-day 7 
female rats but not male rats after neonatal stroke (Renolleau et al., 2007).  Females were 
found to have a significant neuroprotection using Q-VD-OPh because they have a 
caspase-dependent cell death pathway whereas males appear to be independent 
(Renolleau et al., 2008).  However, this was in neonatal rats and not adult rats.  The male 
rat brains may have matured faster than the female rat brains; therefore our study should 
be done using both genders.  In addition, mice have enzymes, called carboxylesterases, 
95 
 
which act as scavengers by acting irreversibly with organophosphorus compounds and 
removing them before they react with actylcholinesterase (Fonnum, 1981; Maxwell et al., 
1987).  This would affect sarin’s exposure on mice and interfere with results, therefore, 
we will treat C57Bl/6 mice with cresylbenzodioxaphosphorin oxide to inhibit 
carboxylesterase scavengers in a murine model optimized for sarin exposure (Garrett et 
al., 2010). 
Studies have demonstrated that CA1 neurons can die by a caspase-dependent, 
active-form of necrosis after status-induced epilepticus with necrotic morphology and 
caspase 3 activation (Lopez-Meraz et al., 2010a).  In these studies, Q-VD-OPh prevented 
neuronal degeneration by 44% (Lopez-Meraz et al., 2010a; Lopez-Meraz et al., 2010b).  
Seizures that are triggered by sarin may induce apoptotic or necrotic neuronal death.  We 
expect Q-VD-OPh to block both cell death types due to the presence of caspase 
activation. 
 To summarize, we designed and synthesized a negative control to analyze 
neuronal death in sarin-exposed mice treated with Q-VD-OPh.  We also optimized the 
Tunel assay and NeuN staining in untreated mice.  These labeling procedures will be 
used to detect neuronal death in the hippocampus of sarin-exposed mice treated with Q-
VD-OPh or Q-VE-OPh. 
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V. APPENDIX 
Appendix A: List of Abbreviations 
ABC  avidin-biotin conjugate  
Apaf-1  apoptotic protease activating factor-1 
BH3  Bcl-2-homology 3 
BSA  bovine serum albumin 
DAB  diaminobenzidine 
DG  dentate gyrus  
Diablo  direct IAP-binding protein with low pI 
DISC  death-inducing signaling complex 
EEG  electroencephalogram 
FADD  Fas-associated death domain 
fmk  fluoromethylketone 
H&E  hematoxylin and eosin  
HRP  horse radish peroxidase 
H2O2  hydrogen peroxide 
NeuN  neuronal neuron 
PBS  phosphate buffer saline 
PBS/T  phosphate buffer saline / triton 
Q-VD-OPh quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxyl]-methyl 
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ketone 
Q-VE-OPh quinolyl-valyl-O-methylglutaryl-[2,6-difluorophenoxyl]-methyl 
ketone 
Smac  second mitochondrial-derived activator of caspases 
Tunel  terminal deoxynucleotidyl transferase-mediated biotinylated UTP 
nick end labeling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
 
 
 
VI. REFERENCES 
Allon N, Chapman S, Egoz I, Rabinovitz I, Kapon J, Weissman BA, Yacov G, Bloch-
Shilderman E, Grauer E.  Deterioration in brain and heart functions following a single 
sub-lethal (0.8 LCt50) inhalation exposure of rats to sarin vapor: A putative mechanism of 
the long term toxicity.  Toxicology Applied Pharmacology.  Vol. 253: 31-37.  2011. 
 
Benchoua A, Guégan C, Couriaud C, Hosseini H, Sampaïo N, Morin D, and Onténiente.  
Specific Caspase Pathways Are Activated in the Two Stages of Cerebral Infarction.  The 
Journal of Neuroscience.  Vol. 21: 7127-7134.  2001. 
 
Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, and Lipton SA.  Apoptosis and 
necrosis: Two distinct events induced, respectively, by mild and intense insults with N-
methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures.  Proceedings of the 
National Academy of Science.  Vol. 92: 7162-7166.  1995. 
 
Braun JS, Prass K, Dirnagl, Meisel A, and Meisel C.  Protection from brain damage and 
bacterial infection in murine stroke by the novel caspase-inhibitor Q-VD-OPH.  
Experimental Neurology.  Vol.206: 183-191.  2007. 
 
Brown TL, Patil S, Basnett RK, and Howe PH.  Caspase inhibitor BD-fmk distinguishes 
transforming growth factor beta-induced apoptosis from growth inhibiton.  Cell Growth 
and Differentiation.  Vol. 9: 869-875.  1998. 
 
Brown TL, Patil S, Cianci CD, Morrow JS, and Howe PH.  Transforming growth factor 
beta induces caspase 3-independent cleavge of alphaII-spectrin (alpha-fodrin) coincident 
with apoptosis.  Journal of Biological Chemistry.  Vol. 274: 23256-23262.  1999. 
 
Brown TL, Patil S, and Howe PH.  Analysis of TGF-beta-inducible apoptosis.  Methods 
of Molecular Biology.  Vol. 142: 149-167.  2000. 
 
Caserta TM, Smith AN, Gultice AD, Reedy MA, and Brown TL.  Q-VD-OPh, a broad 
spectrum caspase inhibitor with potent antiapoptotic properties.  Apoptosis.  Vol. 8: 345-
352.  2003. 
 
Charriaut-Marlangue C, Margaill I, Represa A, Popovici T, Plotkine M, and Ben-Ari Y.  
Apoptosis and Necrosis after reversible focal ischemia: an in situ DNA fragmentation 
analysis.  Journal of Cerebral Blood Flow and Metabolism.  Vol. 16: 186-194.  1996. 
 
99 
 
Chen J, Nagayama T, Jin K, Stetler RA, Zhu RL, Graham SH, and Simon RP.  Induction 
of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after 
transient cerebral ischemia.  The Journal of Neuroscience.  Vol. 18: 4914-4928.  1998. 
 
Choi DW.  Calcium: still center-stage in hypoxic-ischemic neuronal death.  Trends 
Neuroscience.  Vol. 18: 58-60. 1995. 
 
Choi DW.  Ischemia-induced neuronal apoptosis.  Current Opinion in Neurbiology.  
Vol.6: 667-672.  1996. 
 
Colbourne F, Sutherland GR, and Auer RN.  Electron Microscopic Evidence against 
apoptosis as the mechanism of neuronal death in global ischemia.  The Journal of 
Neuroscience.  Vol. 19: 4200-4210.  1999. 
 
Dakshinamurti K and Chauhan J.  Biotin.  Vitamin Hormone.  Vol.45: 337-384.  1989. 
 
Duprez L, Wirawan E, Berghe TV, and Vandenabeele P.  Major cell death pathways at a 
glance.  Microbes and Infection.  Vol. 11: 1050-1062.  2005. 
 
Eichhold TH, Hookfin EB, Taiwo YO, De B, and Wehmeyer KR.  Isolation and 
quantification of fluoroacetate in rat tissues, following dosing of Z-Phe-Ala-CH2-F, a 
peoptidyl fluroromethyl ketone protease inhibitor.  Pharmacology Biomed Anal.  Vol. 16: 
459-67.  1997. 
 
Fiers W, Beyaert R, Declercq W, and Vandenabeele P.  More than one way to die: 
apoptosis, necrosis, and reactive oxygen damage.  Oncogene.  Vol. 18: 7719-7730. 1999. 
Review. 
 
Fonnum F and Sterri SH.  Factors Modifying the Toxicity of Organophosphorus 
Compounds Including Soman and Sarin.  Fundamental and Applied Toxicology.  Vol. 1: 
143-147.  1981. 
 
Fujikawa DG, Shinmei SS, and Cai B.  Lithium-pilocarpine-induced-status epilepticus 
produces necrotic neurons with internucleosomal DNA fragmentation in adult rats.  
European Journal of Neuroscience.  Vol. 11: 1605-1614.  1999. 
 
Fujikawa DG.  Confusion neuronal apoptosis and activation of programmed cell death 
mechanisms in acute necrotic insults.  Trends Neuroscience.  Vol. 9: 410-1. 2000. 
 
Fujikawa DG, Shinmei SS, and CaiB.  Kainic Acid-Induced Seizures produce necrotic, 
not apoptotic, neurons with internuceosomal DNA cleavage implications for programmed 
cell death mechanisms. Neuroscience. Vol.98: 41-53. 2000. 
 
Fujikawa DG, Zhao S, Ke X, Shinmei SS, and Allen SG.  Mild as well as severe insults 
produce necrotic, not apoptotic, cells: Evidence from 60-min seizures.  Neuroscience 
Letters.  Vol. 469: 333-337.  2010. 
100 
 
 
Garrett TL, Rapp CM, Grubbs RD, Schlager JJ, and Lucot JB.  A murine model for sarin 
exposure using the carboxylesterase inhibitor CBDP.  NeuroToxicology.  Vol. 31: 502-
508.  2010. 
 
Gavrieli Y, Sherman Y, Ben-Sasson SA.  Identification of Programmed Cell Death In 
Situ via Specific Labeling of Nuclear DNA Fragmentation.  The Journal of Cell Biology.  
Vol. 119: 493-501.  1992. 
 
Gezginci-Oktayoglu S, Tunali S, Yanardag R, and Bolkent S.  Effects of Z-FA-FMK on 
D-galactosamine/tumor necrosis factor-alpha-induced kidney injury and oxidative stress 
in mice: effects of Z-FA-FMK on TNF-alpha-mediated kidney injury.  Molecular Cell 
Biochemistry.  Vol. 309: 9-20.  2008. 
 
Grauer E, Chapman S, Rabinovitz I, Raveh L, Weissman B, Kadar T, Allon N.  Single 
whole-body exposure to sarin vapor in rats: Long-term neuronal and behavioral deficits.  
Toxicology and Applied Pharmacology.  Vol.227: 265-274. 2008. 
 
Henshall DC, ChenJ, Simon RP.  Involvement of caspase-3-like protease in the 
mechanism of cell death following focally evoked limbic seizures.  Journal of 
Neurochemistry.  Vol. 74: 1215-1223.  2000. 
 
Henshall DC.  Apoptosis signaling pathways in seizure-induced neuronal death and 
epilepsy.  Biochemical Society Transactions.  Vol. 35:421-423. 2007. 
 
Kadar T, Shapira S, Cohen G, Sahar R, Alkalay D, and Raveh L.  Sarin-induced 
neuropathology in rats.  Hum Exp Toxicology.  Vol. 14: 252-259.  1995. 
 
Kajta M.  Apoptosis in the central nervous system: mechanisms and protective strategies.  
Polish Journal of Pharmacology.  Vol. 56: 689-700.  2004. 
 
Khan WA, Dechkovskaia AM, Herrick EA, Jones KH, Abou-Donia MB.  Acute Sarin 
Exposure Causes Differential Regulation of Choline Acetyltransferase, 
Acetylcholinesterase, and Acetylcholine Receptros in the Central Nervous System of the 
Rat.  Toxicology Science.  Vol. 57: 112-120.  2000. 
 
Kondratyev A and Gale K.  Intracerebral injection of caspase-3 inhibitor prevents 
neuronal apoptosis after kainic acid-evoked status epilepticus.  Molecular Brain 
Research.  Vol. 75: 216-224.  2000. 
 
Lallement G, Carpentier P, Collet A, Baubichon D, Pernot-Marino I, and Blanchet G.  
Extracellular ACh changes in Rat Limbic Structures During Soman-Induced Seizures.  
NeuroToxicology.  Vol.13: 557-568.  1992. 
 
Lawerence CP, Kadioglu A, Yang AL, Coward WR, and Chow SC.  The cathepsin B 
inhibitor, z-FA-FMK, inhibits human T cell proliferation in vitro and modulates host 
101 
 
response to pneumococcal infection in vivo.  Journal of Immunology.  Vol.177: 3827-36.  
2006. 
 
Lee JM, Zipfel GJ, and Choi DW.  The changing landscape of ischaemic brain injury 
mechanisms.  Nature.  Vol. 399: A7-A14.  1999. 
 
Leist M, Single B, Castoldi AF, Kϋhnle S, and Nicotera P.  Intracellular Adenosine 
Triphosphate (ATP) Concentration: A Switch in the Decision Between Apoptosis and 
Necrosis.  Journal of Experimental Medicine.  Vol. 185: 1481-1486.  1997. 
 
Leist M. and Jäättelä M.  Four Deaths and a Funeral: From Caspases to Alternative 
Mechanisms.  Nature Reviews Molecular Cell Biology.  Vol.2: 589-598.  2001. 
 
Lopez-Hernandez FJ, Ortiz MA, Bayon Y, and Piedrafita FJ.  Z-FA-fmk inhibits effector 
caspases but not initiator caspases8 and 10, and demonstrates that novel anticancer 
retinoid-related molecules induce apoptosis via the intrinsic pathway.  Molecular Cancer 
Therapy.  Vol. 2: 255-63.  2003. 
 
Lopez-Meraz M, Wasterlain CG, Rocha LL, Allen S, and Niquet J.  Vulnerability of 
postnatal hippocampal neurons to seizures varies regionally with their maturational stage.  
Neurobiology of Disease.  Vol. 37: 394-402.  2010a. 
 
Lopez-Meraz M, Niquet J, and Wasterlain CG.  Distinct caspase pathways mediate 
necrosis and apoptosis in subpopulations of hippocampal neurons after status epilepticus.  
Epilepsia.  Vol. 51: 56-60.  2010b. 
 
Martin LJ, Al-Abdulla NA, Brambrink AM, Kirsch JR, Sieber FE, and Portera-Cailliau 
C.  Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: 
A perspective on the contributions of apoptosis and necrosis.  Brain Research Bulletin.  
Vol. 46:281-309.  1998. 
 
Maxwell DM, Brecht KM, O’Neill BL.  The effect of carboxylesterase inhibition on 
interspecies differences in soman toxicity.  Toxicology Letters.  Vol. 39: 35-42.  1987. 
 
Mattson MP.  Apoptosis in neurodegenerative disorders.  Nature.  Vol.1: 120-129.  2000. 
 
Miyaki K, Nishiwaki Y, Maekawa K, Ogawa Y, Asukai N, Yoshimura K, Etoh N, 
Matsumoto Y, Kikuchi Y, Kumagai N, Omae K.  Effects of Sarin on the Nervous System 
of Subway Workers Seven Years after the Tokyo Subway Sarin Attack.  Journal of 
Occupational Health.  Vol.47: 299-304. 2005 
 
Morita H, Yanagisawa N, Nakajima T, Shimizu M, Hirabayashi H, Okudera H, Nohara 
M, Midorikawa Y, Mimura S.  Sarin poisoning in Matsumoto, Japan.  Lancet.  Vol. 346: 
290-293. 1995 
 
102 
 
Mullen RJ, Buck CR, and Smith AM.  NeuN, a neuronal specific nuclear protein in 
vertebrates.  Development.  Vol. 116: 201-211.  1992. 
 
Murata K, Araki S, Yokoyama K, Okumura T, Ishimatsu S, Takasu N, White RF.  
Asymptomatic sequelae to acute sarin poisoning in the central and autonomic nervous 
system 6 months after the Tokyo subway attack.  J Neurol. Vol.244:601-606. 1997.  
 
Nakajima T, Ohta S, Morita H, Midorikawa Y, Mimura S, Yanagisawa N.  
Epidemiological Study of Sarin Poisoning in Matsumoto City, Japan.  Journal of 
Epidemiology.  Vol. 8: 33-41. 1998.  J Neurol.  Vol.244: 601-606.  1998. 
 
Nicotera P, Leist M, and Manzo L.  Neuronal cell death: a demise with different shapes.  
Trends in Pharmacology Science. Vol.20: 46-51.  1999. 
 
Nishiwaki Y, Maekawa K, Ogawa Y, Asukai N, Minami M, Omae K; Sarin Health 
Effects Study Group.  Effects Sarin Nervous System Rescue Team.  Environmental 
Health Perspectives.  Vol.109: 1169-1173. 2001. 
 
Niquet J, Auvin S, Archie M, Seo D, Allen S, Sankar R, and Wasterlain CG.  Status 
epilepticus triggers caspase-3 activation and necrosis in the immature rat brain.  
Epilepsia.  Vol. 48:1203-1206.  2007. 
 
O’Donnell JC, McDonough JH, Shih TM.  Changes in extracellular striatal acetylcholine 
and brain seizure activity following acute exposure to nerve agents in freely moving 
guinea pigs.  Toxicology Mechanisms and Methods. Vol.20: 143-152. 2010. 
 
Okumura T, Takasu N, Ishimatsu S, Miyanoki S, Mitsuhashi A, Kumada K, Tanaka K, 
Hinohara S.  Report on 640 Victims of the Tokyo Subway Sarin Attack.  Annals of 
Emergency Medicine.  Vol. 28: 129-172. 1996. 
 
Patil S, Wildey GM, Brown TL, Choy L, Derynck R, and Howe PH.  Smad7 is induced 
by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-beta 
induced growth inhibition and apopotosis.  Journal of Biological Chemistry.  Vol. 275: 
38363-38370.  2000. 
 
Paxinos G and Franklin K.  The mouse brain in stereotaxic coordinates.  2
nd
 ed.  San 
Diego, Calif: Academic.  2001. 
 
Renolleau S, Fau S, Goyenvalle C, Joly LM, Chauvier D, Jacotot E, Mariani J, and 
Charriaut-Marlangue C.  Specific caspase inhibitor Q-VD-OPh prevents neonatal stroke 
in P7 rat: a role for gender.  Vol.100: 1067-1073.  2007. 
 
Renolleau S, Fau S, Charriaut-Marlangue C.  Gender-Related Differences in Apoptotic 
Pathways After Neonatal Cerebral Ischemia.  The Neuroscientist.  Vol.14: 46-52.  2008. 
 
103 
 
Ribe EM, Serrano-Saiz E, Akpan N, and Troy CM.  Mechanisms of Neuronal Death in 
Disease: defining the models and the players.  Biochemistry Journal.  Vol. 415: 165-182.  
2008. 
 
Schotte P, Declercq W, Huffel V, Vandenabeele P, and Beyaert R.  Non-specific effects 
of methyl ketone peptide inhibitors of caspases.  FEBS Lett.  Vol. 442: 117-121.  1999. 
 
Seo DW, Lopez-Meraz ML, Allen S, Wasterlain CG, and Niquet J.  Contribution of a 
Mitochondrial Pathway to Excitotoxic Neuronal Necrosis.  Journal of Neuroscience 
Research.  Vol. 87: 2087-2094.  2009. 
 
Southerland B, Kulkarni-Datar K, Keoni C, Bricker R, Grunwald C, Ketcha DM, Hern E, 
Cool DR, and Brown BL.  Q-VE-OPh, a Negative Control for O-Phenoxy-Conjugated 
Caspase Inhibitors.  Journal of Cell Death.  Vol. 3: 33-40. 2010. 
 
Sperandio S, de Belle I, and Bredesen DE.  An Alternative, Nonapoptotic Form of 
Programmed Cell Death.  Proceedings of the National Academy of Science.  Vol. 97: 
14376-14381.  2000. 
 
Stadelmann C and Lassmann H.  Detection of apoptosis in tissue sections.  Cell Tissue 
Research.  Vol. 301: 19-31.  2000. 
 
Suzuki J, Kohno T, Tsukagosi M, Furuhata T, Yamazaki K.  Eighteen Cases Exposed to 
Sarin in Matsumoto, Japan.  Internal Medicine. Vol. 36: 466-470. 1997. 
 
Syntichaki P and Tavernarakis N.  The biochemistry of neuronal necrosis: Rogue 
biology?  Nature.  Vol. 4: 672-684.  2003. Review. 
 
Taylor P.  Anticholinesterase Agents.   Goodman and Gillman’s The Pharmacological 
Basis of Therapeutics.  11
th
 ed.  New York: McGraw-Hill. Chapter 6: 110-129.  1985. 
 
Van Noorden CJ.  The history of Z-VAD-FMK, a tool for understanding the significance 
of caspase inhibition.  Acta Histochemistry.  Vol. 103: 241-52.  2001. 
 
Wang H and Pevsner J.  Detection of endogenous biotin in various tissues: novel 
functions in the hippocampus and implications for its use in avidin-biotin technology.  
Cell and Tissue Research.  Vol. 296:511-516.  1999. 
 
Wiener SW and Hoffman RS.  Nerve Agents: A Comprehensive Review.  Journal of 
Intensive Care Medicine.  Vol. 19: 22-37.  2004. 
 
Wyllie AH and Goldsten P.  More than one way to go.  PNAS.  Vol. 98: 11-13.  2001. 
 
Yamaguchi S and Eto Y.  Diaminobenzidine Peroxidase in Rat Brain.  Experimental 
Neurology.  Vol. 80: 1-8.  1983. 
 
104 
 
Yanagisawa N, Morita H, Nakajima T.  Sarin experiences in Japan: Acute toxicity and 
long-term effects.  Journal of the Neurological Sciences. Vol.249:76-85. 2006. 
 
Zempleni J, Wijeratne S, and Hassan Y.  Biotin.  Biofactors.  Vol. 35: 36-46.  2009. 
 
